Business Context and Reporting Period
This Form 8-K was filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on December 4, 2020. The filing reports on a pre-planned interim analysis of the Company's Phase 2/3 GAIN Trial for its investigational drug, atuzaginstat (COR388), which targets Alzheimer's disease.
Key Financial Metrics
This filing is a Current Report (Item 8.01) regarding a clinical trial update and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Clinical Update
- Interim Analysis Outcome: The independent Data Monitoring Committee (DMC) reviewed data from approximately 300 patients who reached six months of treatment.
- Recommendation: The DMC recommended continuing the trial as planned to the one-year endpoint.
- Findings: The analysis looked for futility, overwhelming efficacy, and safety. The Company remains blinded to all data.
- Timeline: Topline data for the fully enrolled population of 643 subjects is expected in December 2021.
Outlook, Risks, and Management Commentary
Management indicated that the trial will proceed to its full one-year duration. The filing includes standard forward-looking statements regarding the potential success of the GAIN Trial and the therapeutic benefits of atuzaginstat. These statements are subject to substantial risks, including the inherent uncertainties of clinical development and the possibility that actual results may differ materially from expectations. Specific risk factors are referenced in the Company's Form 10-K and Form 10-Q filings.
Investor Verification Checklist
- Verify the registrant name is Cortexyme, Inc. (CRTX), not Quince Therapeutics.
- Confirm the expected topline data release date of December 2021.
- Review the referenced Form 10-K (filed March 16, 2020) and Form 10-Q (filed November 12, 2020) for detailed financial position and risk factors.
- Note that the Company remains blinded to the interim data results.